SecurityRLOG / Rand Logistics, Inc. (752182105)
CEO & PresidentLevy Edward
IndustryWater Transportation
Institutional Owners2
Institutional Shares10,641 - 0.06%
Common Shares Outstanding18,633,149 shares (as of 2017-12-31)
Institutional Value$ 9,000 USD

Institutional Stock Ownership and Shareholders()

RLOG / Rand Logistics, Inc. Institutional Ownership

Rand Logistics, Inc. (OTC:RLOG) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 10,641 shares. Largest shareholders include BlackRock Fund Advisors, and BlackRock Advisors LLC.
Rand Logistics, Inc. (OTC:RLOG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="RLOG / Rand Logistics, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-05-15 13F-HR 1832 Asset Management L.P. 520 0 -100.00 0 0
2018-05-11 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 110,529 0 -100.00 17 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 155 0 -100.00 0 0
2018-05-15 13F-HR JANE STREET GROUP, LLC 16,377 0 -100.00 3 0 -100.00
2017-02-10 13F-HR BlackRock Advisors LLC 5,032 5,032 0.00 4 4 0.00
2018-05-09 13F-HR BlackRock Inc. 13,975 0 -100.00 2 0 -100.00
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 154,628 0 -100.00 24 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 336 0 -100.00 0 0
2018-05-15 13F-HR UBS Group AG 5,033 0 -100.00 1 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 64,368 0 -100.00 10 0 -100.00
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 43,254 0 -100.00 6 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 25,101 0 -100.00 4 0 -100.00
2018-05-11 13F-HR KNOTT DAVID M 185,100 0 -100.00 29 0 -100.00
2018-05-02 13F-HR COBBLESTONE CAPITAL ADVISORS LLC /NY/ 33,837 0 -100.00 5 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 4,529 5,609 23.85 3 5 66.67
2018-05-09 13F-HR NORTHERN TRUST CORP 20,806 0 -100.00 3 0 -100.00
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 33,313 0 -100.00 5 0 -100.00
2018-04-06 13F-HR Kistler-Tiffany Companies, LLC 5,331 0 -100.00 1 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 251,577 0 -100.00 39 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 61,900 0 -100.00 10 0 -100.00

Related Articles

HIMX: Himax Technologies Analysis and Research Report

15h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 752182105